Maja Mockenhaupt

List of Publications by Year in descending order

27 papers	2,880 citations	567281 15 h-index	454955 30 g-index
32 all docs	32 docs citations	32 times ranked	2443 citing authors

#	Article	IF	Citations
1	Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line. Dermatology and Therapy, 2022, 12, 381-393.	3.0	13
2	Epithelial Necrolysis. , 2021, , 409-422.		0
3	Drug Allergy and Cutaneous Adverse Reactions. Handbook of Experimental Pharmacology, 2021, 268, 195-212.	1.8	2
4	Incidence of Epidermal Necrolysis: Results of the German Registry. Journal of Investigative Dermatology, 2020, 140, 2525-2527.	0.7	10
5	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
6	EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 14-27.	5.7	149
7	Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nature Communications, 2019, 10, 3569.	12.8	83
8	Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. Allergo Journal International, 2019, 28, 311-326.	2.0	15
9	HLAâ€B*57:01 confers genetic susceptibility to carbamazepineâ€induced SJS/TEN in Europeans. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2227-2230.	5.7	51
10	Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 283-293.	2.3	38
11	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	2.9	144
12	Radiation-Associated Pemphigus Vulgaris in a Patient With Preceding Malignancy: Treatment With Rituximab as a Valuable Option. Frontiers in Immunology, 2019, 10, 3116.	4.8	9
13	Dr. Maja Mockenhaupt. Nishinihon Journal of Dermatology, 2019, 81, 217-218.	0.0	0
14	Epidermal Necrolysis, Ocular Complications, and â€œCold Medicinesâ€• Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 703-704.	3.8	15
15	Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2017, 153, 514.	4.1	235
16	Fever in Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases. Pediatric Infectious Disease Journal, 2017, 36, 513-515.	2.0	29
17	New Evidence Supporting Cyclosporine Efficacy in EpidermalÂNecrolysis. Journal of Investigative Dermatology, 2017, 137, 2047-2049.	0.7	30
18	The case-crossover design via penalized regression. BMC Medical Research Methodology, 2016, 16, 103.	3.1	4

#	Article	IF	Citations
19	Guideline for the diagnosis of drug hypersensitivity reactions. Allergo Journal International, 2015, 24, 94-105.	2.0	139
20	Effects of immunomodulating therapies on mortality in patients with severe cutaneous adverse reactions in comparison with supportive care only: a systematic review. Clinical and Translational Allergy, 2014, 4, P15.	3.2	1
21	The current understanding of Stevensâ€“Johnson syndrome and toxic epidermal necrolysis. Expert Review of Clinical Immunology, 2011, 7, 803-815.	3.0	237
22	Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study. Journal of Investigative Dermatology, 2008, 128, 35-44.	0.7	807
23	Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. Journal of the American Academy of Dermatology, 2008, 58, 25-32.	1.2	393
24	Epidemiology of Staphylococcal Scalded Skin Syndrome in Germany. Journal of Investigative Dermatology, 2005, 124, 700-703.	0.7	80
25	Evidence of involvement of CXC-chemokines in proliferation of cultivated human melanocytes. International Journal of Molecular Medicine, 2003, 12, 597-601.	4.0	11
26	Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990â€“1992): Structure and results of a population-based registry. Journal of Clinical Epidemiology, 1996, 49, 769-773.	5.0	327
27	Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Evaluation for drug risk based on sale numbers in defined daily doses (DDD). Example of the H2-antagonists. Pharmacoepidemiology and Drug Safety, 1995, 4, 207-212.	1.9	1